Company intelligence / Profile preview
ModeX Therapeutics
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
Overview
ModeX is developing multispecific antibodies and vaccines with the aim of improving efficacy, specificity, and safety over existing therapies. Lead programs target cancer and infectious diseases such as COVID‑19. The company’s lead oncology program uses tetraspecific antibodies to address tumor heterogeneity and resistance. Its infectious disease pipeline includes broadly neutralizing multispecific antibodies against SARS-CoV‑2 Omicron variants with superior potency compared to authorized monoclonal antibodies.[1][2] No late-stage or pivotal clinical results have been reported publicly as of May 2025.
- Therapeutic areas
- HematologyOncologyInfectious Diseases
- Modalities
- Multispecific antibodiesVaccinesFerritin nanoparticle-based biologics[1][2][4]
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ModeX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModeX Therapeutics.